Vertex Breakfast Symposium: "Conversation with CF experts on treating pre-school children with CFTR modulators: What have we learnt so far?"
| Monday, March 25, 2024 |
| 7:15 AM - 8:15 AM |
| Meeting Room 5 |
|
Sponsored By:
Vertex Pharmaceutical
|
Details
The first CFTR (cystic fibrosis transmembrane conductance regulator) modulator, KALYDECO® (ivacaftor), was TGA approved in July 2013. Since then, multiple CFTR modulators have been approved: ORKAMBI® (lumacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor). With the demonstration of safety and efficacy, these modulators have been expanded to broader and younger age groups.
There is much to be learned from the clinical experience to date with these CFTR modulators that can be applied to treating children with cystic fibrosis (CF). This one-hour educational meeting will be conducted in panel discussion format where Australian CF experts will share their clinical experience, discuss how they apply their learnings to treating younger patients as soon as treatment is available and address topical questions related to initiating CFTR modulators in pre-school children.
Speaker
Associate Professor Tonia Douglas
Consultant
Queensland Children’s Hospital
Conversation with CF experts on treating pre-school children with CFTR modulators: What have we learnt so far?
Biography
Associate Professor Tonia Douglas is the co-director for paediatric CF services in Queensland and a specialist respiratory and sleep physician. She is the chair of the steering committee for the Standards of Care for CF in Australia 2023 setting expectations for paediatric and adult care in the new era of CFTR modulator therapies. Tonia has held chair positions on the steering committees for the past three Shift symposiums and is passionate about driving health care excellence in CF. She is a clinical associate professor with the University of Queensland Medical School and her research focus is the psychosocial health of children and adolescents with CF and relationships between mental health and clinical outcomes.
Prof Claire Wainwright
SMO Respiratory Medicine
University of Queensland / Queensland Children's Hospital
Conversation with CF experts on treating pre-school children with CFTR modulators: What have we learnt so far?
Biography
Professor Claire Wainwright is a paediatric respiratory physician and Co-Lead for CF services at the Queensland Children’s Hospital in Brisbane which manages around 470 children with CF across Queensland and northern NSW. She is a Professor of paediatrics and child health at the University of Queensland and her research interests include clinical trials, development of lung disease in CF, airway microbiology, and patient reported outcomes in CF.
Prof Adam Jaffe
Professor of Paediatrics
Sydney Children's Hospital
: Conversation with CF experts on treating pre-school children with CFTR modulators: What have we learnt so far?
Biography
Prof Jaffe is the John Beveridge Professor of Paediatrics and Head of the Discipline of Paediatrics and Child Health, School of Clinical Medicine at UNSW Sydney, and Paediatric Respiratory Consultant at Sydney Children’s Hospital. Prof Jaffe undertook his MD thesis in gene therapy for children with cystic fibrosis at Imperial College, London. Previously he was Consultant in Respiratory Research at Great Ormond Street Hospital for Children, London before moving to Australia in 2006. His main research interest is in translational research in children with cystic fibrosis and other rare childhood lung diseases, and is the Director of the miCF Research Laboratory for Precision Medicine in Cystic Fibrosis. He is the chair of the Asthma Australia Research Advisory Committee and Rare Voices Australia Scientific and Medical Advisory Committee.
Prof Andre Schultz
Physician
Perth Children's Hospital
Conversation with CF experts on treating pre-school children with CFTR modulators: What have we learnt so far?
Biography
André Schultz is a physician-researcher based at Perth Children’s Hospital, Program Head of Respiratory Health at Telethon Kids Institute and Honorary Clinical Professor at the University of Western Australia. He is a MRFF Investigator and previous NHMRC TRIP Fellow. He is Deputy Chair of the Australian Cystic Fibrosis Data Registry Steering Committee, a Chief Investigator for the Centre for Research Excellence in Respiratory Health of Aboriginal and Torres Strait Islander Children (AusBREATHE), and President of the Australian Council of Smoking and Health. His research focuses on improving lifelong health trajectories from early childhood, particularly for vulnerable populations.
